Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See More
Dear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
See MoreDear Customer, If you experience any text readability or display issues on our website, please update your web browser to the latest version
.
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location site or be switched to your location?
Differential expression of CD45.2 on splenocytes from BALB/c and SJL mouse strains. Splenocytes from BALB/c (solid line) or SJL (dashed line) mice were stained with APC conjugated anti- mouse CD45.2 clone 104 and analyzed by flow cytometry. Flow cytometry was performed on a BD FACSCalibur™ instrument and the histograms were derived from the gated events based on light scattering characteristics of viable splenocytes.
Differential expression of CD45.2 on splenocytes from BALB/c and SJL mouse strains. Splenocytes from BALB/c (solid line) or SJL (dashed line) mice were stained with APC conjugated anti- mouse CD45.2 clone 104 and analyzed by flow cytometry. Flow cytometry was performed on a BD FACSCalibur™ instrument and the histograms were derived from the gated events based on light scattering characteristics of viable splenocytes.
Differential expression of CD45.2 on splenocytes from BALB/c and SJL mouse strains. Splenocytes from BALB/c (solid line) or SJL (dashed line) mice were stained with APC conjugated anti- mouse CD45.2 clone 104 and analyzed by flow cytometry. Flow cytometry was performed on a BD FACSCalibur™ instrument and the histograms were derived from the gated events based on light scattering characteristics of viable splenocytes.
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
The 104 monoclonal antibody recognizes the CD45 (Leukocyte Common Antigen) present on all leucocytes of most mouse strains (eg, A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). This alloantigen was originally named Ly-5.1, and this was the designation at the time that the antibody was characterized. The designation was later changed from Ly-5.1 to Ly-5.2 to conform with the convention that the .2 alloantigen designations be assigned to the C57BL/6 strain. mAb 104 has been reported not to react with leucocytes of the mouse strains expressing the CD45.1 alloantigen (eg, RIII, SJL/J, STS/A, and DA). CD45 is a member of the Protein Tyrosine Phosphatase (PTP) family: its intracellular (COOH-terminal) region contains two PTP catalytic domains, and the extracellular region is highly variable due to alternative splicing of exons 4, 5, and 6 (designated A, B, and C, respectively), plus differing levels of glycosylation. The CD45 isoforms detected in the mouse are cell type-, maturation-, and activation state-specific. The CD45 isoforms play complex roles in T-cell and B-cell antigen receptor signal transduction. The 104 antibody has been reported to inhibit some responses of B cells, from mice expressing the CD45.2 alloantigen, to certain antigens and LPS. In addition, reduction of serum IgG levels and amelioration of autoimmune renal pathology were reported in mAb 104-treated systemic lupus erythematosus-prone mice.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.